Lupic Outbreak and Covid-19 Pneumonia-Case Report

Tamayo Ortiz Jose Luis1*, Bello Quesada Manuel2, Camputaro Luis3, Glenda Regina Escobar Pérez4, Jesus del Carmen Cerritos Navarro5, Romina Georgina Bórtoli6, Rodzeno de Mendez Esperanza Beatriz7, Solorzano Landaverde Steffany Magela8, Escalante Contreras Malissa Andrea9

1Hospital Nacional El Salvador. Physician, Intensive Care Department. San Salvador-El Salvador.
2Hospital Nacional El Salvador. Physician, Head of the Intensive Care Department. San Salvador-El Salvador.
3Hospital Nacional El Salvador. Physician, Head of Teaching and Research Department. San Salvador-El Salvador.
4Hospital Nacional El Salvador. Resident Physician, Intensive Care Department. San Salvador-El Salvador.
5Hospital Nacional El Salvador. Resident Physician, Intensive Care Department. San Salvador-El Salvador.
6Hospital Nacional El Salvador. Physician, Intensive Care Department. San Salvador-El Salvador.
7Hospital Nacional El Salvador. Physician, Intermediate Care Coordinator, Intensive Care Department. San Salvador-El Salvador.
8Student, fifth year medical degree, Universidad Jose Matias Delgado. San Salvador-El Salvador.
9Corresponding Author: Tamayo Ortiz Jose Luis, Hospital Nacional El Salvador. Physician, Intensive Care Department. San Salvador-El Salvador.

Received Date: 24 June 2021 | Accepted Date: 13 July 2021 | Published Date: 21 July 2021

Citation: Tamayo Ortiz JL, Bello Quesada M, Camputaro LA, et al. (2021) Lupic Outbreak and Covid-19 Pneumonia-Case Report. International Journal of Clinical Case Reports and Reviews. 7(5); DOI: 10.31579/2690-4861/152

Copyright: © 2021 Emadia Alaki, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract
Coronavirus disease 2019 (COVID-19) is a respiratory infection that can cause mild symptoms or even death, to patients who suffer from it. It affects all population groups without distinction. Systemic Lupus Erythematosus (SLE) is a chronic and fluctuating autoimmune disease. One of the goals of the treatment is to avoid flare-ups and thereby reduce mortality. Their innate alterations in immunity, added to the use of immunosuppressive drugs to control the disease and prevent outbreaks, it makes them more vulnerable to develop severe symptoms in the course of SARS-CoV-2 infection. We present the case of a patient with SLE infected by SARS-CoV-2 with a lupus flare during hospitalization, entailing a diagnostic and therapeutic challenge.

Key words: sle, covid-19, lupus-flare, sars-cov-2

Introduction
It has been more than a year (March 11, 2020) since the World Health Organization (WHO) declares the coronavirus disease 2019 (COVID-19) as a pandemic [1]. There are still many questions about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In its mild form, infected patients develop well-tolerated respiratory, gastrointestinal, and neurological symptoms, but in its severe form they can developed septic shock and multiple organ failure [2-4]. The most affected populations are the elderly and especially those with comorbidities. The immune response plays an important role against viral diseases, both as antiviral defense and in disease progression. Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune and multisystemic disease with a fluctuating clinical course. It mainly affects women, being more prevalent African and Hispanic [5]. Research has been conducted prior to the pandemic showing that patients with SLE are at increased risk of infection, a risk that is greater if patients have higher levels of disease activity, the use of corticosteroids on a regular basis, or who have previously received treatment with cyclophosphamide or rituximab [6,7]. However, some studies suggest that immunosuppression secondary to SLE management may be beneficial by reducing the immune system’s response to COVID-19 [8-9], while other studies report that intense immunosuppression does not allow an effective antiviral response to the exposure to COVID-19, triggering a more severe form of the disease [10,11]. The COVID-19 global rheumatology alliance reported one of the largest series of 600 Covid-19 patients, with various underlying rheumatological disorders from 40 countries. Although the study did not report on the incidence of Covid-19 in these patients, although describes that a glucocorticoid dose greater than 10 mg per day was associated with a higher chance of hospitalization [12]. Despite the various available treatment options at present, only 20-30% of patients with SLE have an inactive or active chronic disease [13,14], the rest experiment flare-ups periods that can cause permanent organic damage with increase of morbidity, mortality, and health costs [15-19].

The consensus definition of lupus flare refers to a measurable increase in the disease activity involving new or worse clinical signs and symptoms and/or laboratory markers. This should be considered clinically significant by the physician and generally leads to evaluate a treatment change or upscale [20]. Of the Instruments available and used to date to assess disease activity, the SLE Disease Activity Index (SLEDAI) with modifications (SLEDAI 2K, SELENA-SLEDAI) [21] and the British Isles Lupus Assessment Group 2004 (BILAG 2004) [22] are the most widely used in both clinical practice and research studies. SLEDAI reflects disease activity in the last 30 days and has a significant prognosis value of mortality in the next 6 months [23]. Among the serological
markers, the increase in the titers of the anti-dsDNA double-chain antibody, and the low levels of complement are part of the evaluation.

The European League against Rheumatism (EULAR) guide, within its recommendations establishes that outbreaks can be treated according to the severity of organ involvement by adjusting ongoing therapies (glucocorticoids, immunomodulatory agents) to higher doses, changing, or adding new therapies. The goal of preventing flare-ups is to avoid permanent organ damage and thereby improve the prognosis [24].

Strict control and monitoring are a fundamental part to reduce outbreaks in patients with SLE, however, the coronavirus pandemic has limited controls in this type of patients given that exposing them to public and hospital circulation leads to an increased risk of contagion. This situation generated a higher risk of poor adherence, greater presence of decompensations, outbreaks or worsening and the possibility of coexisting a flare and coronavirus infection.

The following report is a clinical case of a patient with lupus outbreak and SARS-COV-2 infection.

**Case Presentation**

A 23-year-old female patient with history of systemic lupus erythematosus (SLE) approximately diagnosed 3 years ago with lupus nephritis and HBP.

Usual medication: cyclosporine 100 mg/day, mycophenolate 250 mg every 8 hours, enalapril 10 mg day, ASA (acetylsalicylic acid) 100 mg/day, Omeprazole, Furosemide 40 mg / day.

She consulted in a peripheral hospital due to clinical presentation characterized by persistent non-productive cough associated with dyspnea on moderate efforts. She was admitted for COVID-19 suspicion and treatment according to the Covid-19 Protocol was initiated. Faced with the refusal of the diagnosis by relatives, voluntary discharge is requested and she continued with outpatient medical treatment. At home, she continued with persistent cough, fever, adds anosmia, ageusia and progression of dyspnea. On 01/14/2021, after 1 month of clinical symptoms, she re-entered the peripheral hospital and later was transferred to El Salvador’s National Hospital.

At Emergency area of Hospital El Salvador, the patient present desaturation, fever and drowsiness. Vital signs upon admission: BP: 128/65mmHg, HR: 148 bpm, RR: 28 rpm, SatO2: 88%, T °: 38.5°. Laboratory admission: Hematocrit: 39.2%, Hemoglobin: 13.4 gr/dl, Platelets: 358,000, White blood cells: 7,600, Neutrophils: 93.9%, Lymphocytes: 3.30%, Urea: 39.1 mg/dl, Creatinine: 0.68 mg/dl, Sodium: 139 meq/l, Potassium: 5.3 meq/l, AST U/I: 115, ALT: 36.9 U/I, LD: 662 U/I, CRP = 8.1 mg/l, Ferritin: 2065 ng/ml, IL6: 33.8, Fibrinogen: 349 mg/dl, DD: 2824.98 mg/l. She was admitted to the intensive care unit and started with ventilatory support with a reservoir mask, achieving SatO2: 95%. The COVID-19 Protocol continues. A chest X-ray is performed (Fig.1) which shows bilateral infiltrates left predominantly, and bilateral blunting of costophrenic angles. Arterial blood gas: PH: 7.38, PCO2: 33.5, PO2: 65.9, HCO3: 20.1, SatO2: 92%. COVID-19 treatment protocol was continued during hospitalization.

![Figure 1: Chest X-ray](image)

Twenty four hours after admission the patient presented drowsiness, delirium, radiographic infiltrates progression, hypoxemia, increased breathing effort and arterial hypertension. Oxygen support device was change to a high-flow cannula and set with the following parameters: 50 lts/min flow and fio2 50%, improving saturation to 96%. Thoracic (Fig. 2,3,4) and abdominal (Fig. 5,6) CT scan without contrast was performed, it showed: multiple ground glass opacities in both lung fields, which compromise more than 75% of each one, in addition there is subpleural septal thickening, bilateral basal subpleural bands, and some areas of subpleural honeycombing changes in the apex. In addition, pericardial effusion with a thickness of up to 3.2 cm extends to the pericardial recesses. Basal bilateral laminar pleural effusion was also observed. In the mediastinum, some inflammatory nodes are identified. As an incidental finding, the presence of free perihepatic, perisplenic fluid, was an incidental finding in upper abdomen. Both kidneys enlarged, swollen, with bilateral pararenal laminar fluid. Soft tissues and bone structures present no abnormalities.
Figure 1: Thoracic CT scan without contrast

Figure 2: Thoracic CT scan without contrast

Figure 3: Abdominal CT scan without contrast
Clinical finding seven days after admission suggested deep vein thrombosis in right inferior limb and venous doppler scan shows right femoral and saphenous vein thrombosis. Due to COVID-19 protocol the patient received anticoagulation treatment with enoxaparin 1 mg/kg/day, dose was increased to 1 mg/kg every 12 hours, and antiplatelet agents were add. Given the CT scan findings associated with arterial hypertension and altered level of consciousness, in addition to COVID-19 pneumonia, clinical signs of lupus outbreak are suspected. SLEDAI scale is performed: 20 (Organic brain syndrome: 8, Urinary casts: 4, Proteinuria: 4, Pleurisy: 2, Pericarditis: 2), corresponding to high activity or very high activity. A general urine test and 24 hrs urine collection test informed: Creatinine clearance: 56 ml / min, proteins in 24 hrs: 6.31 gr / 24hrs. Given these findings with high suspicion of a lupus outbreak and without evidence of active infection (negative cultures), it was decided to start pulse corticosteroid therapy at a dose of 1 gram / day for 3 days. The patient evolves favorably with remission of arterial hypertension, drowsiness, headache, delirium, without progression of respiratory failure. Corticosteroids were tapered down until 10 mg per day is achieved, then immunosuppressive treatment is started. During hospitalization the patient presented asymmetric edema of the left upper limb. Due to deep venous thrombosis clinical suspicion, a vascular doppler was performed, which informed left upper limb cephalic vein thrombosis. Anticoagulation with oral anticoagulants was prescribe.

Discussion

The present case report represents a great medical dilemma, due to diagnostic approach and therapeutic decisions complexity of patients with chronic multisystemic diseases admitted to critical care units [8-11]. Patients with SLE in an advanced-stage renal failure represent a medical challenge itself, in this case report severe COVID-19 pneumonia obscure the medical diagnosis. Despite the substantial bilateral involvement of the lung parenchyma, the latent risk of mechanical ventilation gradually decreased over the hospitalization. However, we noticed clinical manifestations (altered level of consciousness, fever, joint pain, arterial hypertension), laboratory and imaging (proteinuria, increased inflammatory parameters, serositis) that could not be fully attributed to COVID-19, which generated a reasonable clinical uncertainty of a Lupus Outbreak [20].

To corroborate our clinical suspicion all the methods available in our institution were performed [21-22], to prescribe corticosteroid pulses therapy because of the risk that this therapy entails. The use of corticosteroids is justified in the lupus flare [24], but in COVID-19 there was no evidence available of the benefit of corticosteroids until the publication of the RECOVERY study [25] and to date the METCOVID trial did not show benefit in mortality to 28 days in those under 60 years of age [26]. In the present clinical case, it was pondered the lupus outbreak as the principal cause of the patient's health deterioration, for which the decision was made to perform corticosteroid pulses therapy, achieving remission of symptoms, reduction of inflammatory parameters and clinical...
improvement significant. Based on the clinical evolution, we can interpret the benefit of the therapy with high-dose corticosteroids pulsed in relation to the lupus flare, but we do not know if it could have contributed to limit the COVID 19 cytokine storm [27].

**Conclusion and Final Considerations**

Patients with autoimmune and immunosuppressed diseases always present a great challenge when they are admitted to the critical care unit. We have witnessed that COVID-19 presents a great challenge when they are admitted to the critical care unit. Patients with SLE, SLEDAI, and SLEDAI 2K: Systemic Lupus Erythematosus Disease Activity Index and SELENA SLEDAI: The Safety of Estrogens in Lupus Erythematosus-National Assessment Trial SLEDAI-BILAG 2004: British Isles Lupus Assessment group present a great challenge when they are admitted to the critical care unit. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: the Manhattan lupus surveillance program. Arthritis & Rheumatology. 69(10):2006-2017. 6. Jung JY, Yoon D, Choi Y, Kim HA, Suh CH. (2019) Associated clinical factors for serious infections in patients with systemic lupus erythematosus. Scientific reports. 9(1):1-8.

7. Bosch X, Guilabert A, Pallares L, Cervera R, Ramos-Casals M, Bové A, Ingelmo M, Font J. (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. 15(9):584-589.

8. So H, Mak JW, Tam LS. (2020) No systemic lupus erythematosus with COVID-19 in Hong Kong: the effect of masking?. The Journal of Rheumatology. 47(10):1591.

9. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Annals of the rheumatic diseases. 79(5):667-668.

10. Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, Cozzi G, Depascale R, Zanatta E, Gasparotto M, Benvenuti F. (2020) SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. Journal of autoimmunity. 112:102502.

11. Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, Barrelet A, Chauvet C, Chazal T, Delahousse M, Devaux M. (2020) Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Annals of the rheumatic diseases. 79(6):837-839.

12. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsbohn L, Kutz P, Lawson-Tovey S, Matus EF. (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the rheumatic diseases. 79(7):859-866.

13. Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 42(12):2682-2688.

14. Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB. (2019) Disease course patterns in systemic lupus erythematosus. Lupus. 28(1):114-122.

15. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. (2004) Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology. 43(8):1039-1044.

16. Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, Pastor-Asurza CA, Alfaro-Lozano JL, Cucho-Venegas JM, Segami MI, Woydyla D, Soriano ER, Drenkard C, BrenolJC. (2015) The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Annals of the rheumatic diseases. 74(6):1019-1023.

17. Fernandez D, Kirou KA. (2016) What causes lupus flares?. Current rheumatology reports. 18(3):14.

18. Kan HJ, Song X, Johnson BH, Bechtel B, O’ Sullivan D, Molta CT. (2013) Healthcare utilization and costs of systemic lupus erythematosus in Medicaid. BioMed research international.

19. Drenkard C, Bao G, Dennis G, Kan HJ, Jhingran PM, Molta CT, Lim SS. (2014) Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States. Arthritis care & research. 66(6):878-887.

20. Ruiz-Palacios GM, Alarcón GS, Belmont HM, Brey RL, Brunetta P, Buyon JP, Costner ML, Cronin ME, Dooley MA, Filocamo G. (2011) International consensus for a definition of disease flare in lupus. Lupus. 20(5):453-462.
21. Gladman DD, Ibanez D, Urowitz MB. (2002) Systemic lupus erythematosus disease activity index 2000. The Journal of Rheumatology. 29(2):288-291.
22. Isenberg DA, Rahman A, Allen EB, Farewell V, Akil M, Bruce IN, D’cruz D, Griffiths B, Khamashta M, Maddison P, McHugh N. BILAG. (2005) Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology. 44(7):902-906.
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, Bell A, Bloch DA, Corey PN, Decker JL, Esdaile J. (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 35(6):630-640.
24. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F. (2019) update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the rheumatic diseases. 78(6):736-745.
25. RECOVERY Collaborative Group. (2021) Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine. 384(8):693-704.
26. Jeronimo CM, Farias ME, Val FF, Sampaio VS, Alexandre MA, Melo GC, Safe IP, Borba MG, Abreu-Netto RL, Maciel AB, Neto JR. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19: a randomised, double-blind, phase IIb, placebo-controlled trial.
27. Moore JB, June CH. (2020) Cytokine release syndrome in severe COVID-19. Science. 368(6490): 473-474.